VIYASH259.00

Viyash Scientific Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSYATHARTHTHYROCARESUPRIYASTARSPARCSHILPAMEDRUBICONMcap ₹11,314 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation61.566.5233.6
+ Finance Costs48.160.869.2
+ Interest Income-0.7-2.7-9.3
+ Fair Value (Gains) / Losses-0.00.00.0
+ Share-based Payments0.032.436.3
+ Unrealised FX (Gain) / Loss15.48.1-6.6
+ Other Non-cash Items31.6-9.950.6
+ Other — Cash Effects are Investing / Financing-11.00.0-9.5
Changes in Working Capital
+ Inventories0.3-46.9-103.9
+ Trade Receivables — Current-8.8-47.9-284.1
+ Other Current Assets-0.0-0.00.0
+ Other Bank Balances0.00.0-0.1
+ Trade Payables — Current-37.16.458.9
Cash from Operating Activities
Profit Before Tax (per I/S)-54.644.3349.0337.9
+ Total Adjustments (incl. Working Capital)99.366.735.2
Cash from Operations (pre-tax)44.7111.0384.2
+ Income Taxes Paid14.127.661.3
Cash from Operating Activities30.683.4322.9
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)30.839.1134.7
+ Disp of Fixed Assets19.29.736.9
+ Acq of Other Long-term Assets5.70.00.0
+ Disp of Other Long-term Assets0.00.02.9
+ Interest Received — Investing0.62.59.8
+ Other Inflows / (Outflows) — Investing10.92.21.1
Cash from Investing Activities-5.9-24.8-84.1
Cash from Financing Activities
+ Proceeds from Issue of Shares0.00.039.5
+ Proceeds from Other Equity Instruments0.00.092.5
+ Proceeds from Exercise of Stock Options0.00.039.9
+ Proceeds from Borrowings113.3268.25.2
+ Repayment of Borrowings58.5270.8212.9
+ Payment of Lease Liabilities0.012.513.6
+ Payment of Finance Lease Liabilities10.8
+ Interest Paid45.351.369.0
+ Dividends Paid0.01.94.9
+ Other Inflows / (Outflows) — Financing-0.17.50.0
Cash from Financing Activities-1.4-60.7-123.3
Net Changes in Cash (pre-FX)23.2-2.2115.5
Net Changes in Cash23.2-2.2115.5
Closing Cash64.8
Reference Items
EBITDA61.4161.8652.5593.9
EBITDA Margin %4.4810.4319.0818.86
Free Cash Flow (CFO − Capex)-0.244.3188.2188.2
Free Cash Flow to Equity-11.9108.6
Free Cash Flow per Basic Share-0.001.014.314.31
Price to Free Cash Flow60.12
Cash Flow to Net Income-1.032.581.44
Cash Paid for Taxes14.127.661.3
Cash Paid for Interest45.351.369.0
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.